ES2171669T3 - Composicion farmaceutica que contiene hidrocloruro de tiagabina y su procedimiento de preparacion. - Google Patents

Composicion farmaceutica que contiene hidrocloruro de tiagabina y su procedimiento de preparacion.

Info

Publication number
ES2171669T3
ES2171669T3 ES96913473T ES96913473T ES2171669T3 ES 2171669 T3 ES2171669 T3 ES 2171669T3 ES 96913473 T ES96913473 T ES 96913473T ES 96913473 T ES96913473 T ES 96913473T ES 2171669 T3 ES2171669 T3 ES 2171669T3
Authority
ES
Spain
Prior art keywords
thiagabine
pharmaceutical composition
composition containing
hydrocloride
preparation procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96913473T
Other languages
English (en)
Inventor
Jorgen Ryhl Svensson
Lars Nygaard
Tina Meinertz Andersen
Helle Weibel
Thyge Borup Hjorth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Application granted granted Critical
Publication of ES2171669T3 publication Critical patent/ES2171669T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCION DESCRIBE UNA NUEVA COMPOSICION FARMACEUTICA ESTABLE QUE CONTIENE CLORHIDRATO DE TIAGABINA COMO PRINCIPIO ACTIVO.
ES96913473T 1995-05-05 1996-04-29 Composicion farmaceutica que contiene hidrocloruro de tiagabina y su procedimiento de preparacion. Expired - Lifetime ES2171669T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK52395 1995-05-05

Publications (1)

Publication Number Publication Date
ES2171669T3 true ES2171669T3 (es) 2002-09-16

Family

ID=8094516

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96913473T Expired - Lifetime ES2171669T3 (es) 1995-05-05 1996-04-29 Composicion farmaceutica que contiene hidrocloruro de tiagabina y su procedimiento de preparacion.

Country Status (26)

Country Link
US (1) US5866590A (es)
EP (1) EP0830132B1 (es)
JP (1) JP3195360B2 (es)
KR (1) KR100440354B1 (es)
CN (1) CN1092959C (es)
AR (1) AR003418A1 (es)
AT (1) ATE211911T1 (es)
AU (1) AU707508B2 (es)
BR (1) BR9608120A (es)
CA (1) CA2220019C (es)
CZ (1) CZ292256B6 (es)
DE (1) DE69618586T2 (es)
DK (1) DK0830132T3 (es)
EG (1) EG23781A (es)
ES (1) ES2171669T3 (es)
HU (1) HU223075B1 (es)
IL (1) IL118142A (es)
MX (1) MX9708394A (es)
MY (1) MY115016A (es)
NO (1) NO318599B1 (es)
NZ (1) NZ307159A (es)
PL (1) PL183678B1 (es)
PT (1) PT830132E (es)
UA (1) UA43402C2 (es)
WO (1) WO1996034606A1 (es)
ZA (1) ZA963478B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914333A (en) * 1996-07-31 1999-06-22 Novo Nordisk A/S Treatment of psychotic disorders
EP0991409B1 (en) * 1997-08-01 2002-01-30 ELAN CORPORATION, Plc Controlled release pharmaceutical compositions containing tiagabine
IE970588A1 (en) 1997-08-01 2000-08-23 Elan Corp Plc Controlled release pharmaceutical compositions containing tiagabine
EP1017386A1 (en) * 1997-10-02 2000-07-12 H. Lundbeck A/S GRANULAR PREPARATIONS OF 5-(2-ETHYL- 2$i(H)-TETRAZOL- 5-YL)-1-METHYL-1, 2,3,6-TETRAHYDROPYRIDINE
FR2771292B1 (fr) * 1997-11-21 2000-02-18 Ethypharm Lab Prod Ethiques Spheroides contenant de la tiagabine, procede de preparation et compositions pharmaceutiques
ZA99407B (en) * 1998-01-22 1999-07-20 Abbott Lab Extended release tiagabine formulations with reduced side-effects.
AU2002325404B2 (en) * 1998-01-22 2006-02-02 Abbott Laboratories Extended Release Tiagabine Formulations with Reduced Side-effects
WO2001091751A1 (en) * 2000-05-30 2001-12-06 Novo Nordisk A/S New pharmaceutical composition and the process for its preparation
JP2004506609A (ja) 2000-05-26 2004-03-04 ノボ　ノルディスク　アクティーゼルスカブ 新たなる医薬組成物及びその調製の為の方法
WO2006067605A1 (en) * 2004-12-23 2006-06-29 Ranbaxy Laboratories Limited Stable pharmaceutical compositions of tiagabine and processes for their preparation
CN102125693A (zh) * 2011-01-25 2011-07-20 福建科瑞药业有限公司 一种盐酸噻加宾药物组合物及其制备方法
SG11201407309XA (en) * 2012-05-08 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of epilepsy
JP6793651B2 (ja) * 2015-08-28 2020-12-02 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US501090A (en) * 1893-07-11 gennert
DK288385D0 (da) * 1985-06-26 1985-06-26 Novo Industri As Aminosyrederivater
DK58291D0 (da) * 1991-04-02 1991-04-02 Novo Nordisk As Krystalinsk stof og dets fremstilling
WO1995005808A1 (en) * 1993-08-24 1995-03-02 Abbott Laboratories Oil-based tableting method
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies

Also Published As

Publication number Publication date
AR003418A1 (es) 1998-08-05
HUP9802741A3 (en) 1999-04-28
NZ307159A (en) 1998-10-28
CZ338897A3 (cs) 1998-03-18
EP0830132B1 (en) 2002-01-16
US5866590A (en) 1999-02-02
DK0830132T3 (da) 2002-04-29
MX9708394A (es) 1998-02-28
CA2220019A1 (en) 1996-11-07
PL183678B1 (pl) 2002-06-28
WO1996034606A1 (en) 1996-11-07
CN1183721A (zh) 1998-06-03
ZA963478B (en) 1996-11-13
CN1092959C (zh) 2002-10-23
NO975076L (no) 1997-11-04
EP0830132A1 (en) 1998-03-25
AU5644196A (en) 1996-11-21
HUP9802741A2 (hu) 1999-03-29
BR9608120A (pt) 1999-02-09
EG23781A (en) 2007-08-13
UA43402C2 (uk) 2001-12-17
ATE211911T1 (de) 2002-02-15
CA2220019C (en) 2007-12-11
JPH10505359A (ja) 1998-05-26
NO318599B1 (no) 2005-04-18
MY115016A (en) 2003-03-31
NO975076D0 (no) 1997-11-04
IL118142A (en) 1999-11-30
CZ292256B6 (cs) 2003-08-13
DE69618586T2 (de) 2002-09-05
KR100440354B1 (ko) 2004-09-18
PT830132E (pt) 2002-07-31
IL118142A0 (en) 1996-09-12
JP3195360B2 (ja) 2001-08-06
HU223075B1 (hu) 2004-03-01
PL323138A1 (en) 1998-03-16
AU707508B2 (en) 1999-07-15
DE69618586D1 (de) 2002-02-21

Similar Documents

Publication Publication Date Title
PT1121104E (pt) Novas formulacoes orais de libertacao controlada
ES2176421T3 (es) Composicion topica gelificada estable que contiene un electrolito, un agente activo y etil hidroxietilcelulosa.
ES2156603T3 (es) Medicamentos a base de una mezcla sinergetica de metronidazol y de clindamicina.
CR6392A (es) Moduladores de ccr5
HUP0301491A2 (hu) Foto-labilis elő illatanyag-konjugátumok
BR0110767A (pt) Derivados de piperidina farmaceuticamente ativos, em particular como moduladores da atividade de receptor de quimiocina
ES2171669T3 (es) Composicion farmaceutica que contiene hidrocloruro de tiagabina y su procedimiento de preparacion.
BR9916585A (pt) Moduladores de ccr5
ES2138271T3 (es) Compuestos de 6-dimetil-amino-metil-1-fenil-ciclohexano como principio activo farmaceutico.
ES2123323T3 (es) Asociacion de un compuesto con actividad antimicrobiana (por ejemplo lipoaminoacido n,n-octanoilglicina) y de un monoalquileter de glicerol y su uso como agente antimicrobiano.
HN2002000247A (es) Derivados de sulfonamida
ATE224717T1 (de) Oral anzuwendende arzneizubereitungen enthaltend eine benzhydrylpiperazine und eine zyklodextrin
ES2176700T3 (es) Composiciones para la piel.
BR0105899A (pt) Agente cosmético pulverulento e processo para a sua preparação
ES2171533T3 (es) Composiciones que contienen nebivolol micronizado.
SE9301171D0 (sv) Pharmaceutical composition containing lipophilic drugs
AR032293A1 (es) Estuche farmaceutico
GT199800101A (es) Composicion farmaceutica solida que contiene un derivado de benzofurano.
PA8466601A1 (es) Nuevas amidas aromaticas, su procedimiento de preparacion y su aplicacion como medicamentos
DE69921318D1 (de) Tensid für äusserlich anzuwendende hautpräparate und diese beinhaltende äusserlich anzuwendende hautpräparate
BR0114059A (pt) Derivados de resorcinol
BRPI0017528B8 (pt) uso de uma composição contendo sal de cetotifeno
HN1998000144A (es) Formulacion medicamentosa con liberacion controlada de sustancia activa.
DE50007791D1 (de) Parfümkomposition mit duftsequenz
DK1330258T3 (da) Kahalalid F-formulering

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 830132

Country of ref document: ES